Metabolic effects of the atypical antipsychotics.
Wooten
James
J
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000009:adverse effects; D003024:Clozapine / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000378:metabolism; D003987:Dibenzothiazepines / Q000009:adverse effects; D050171:Dyslipidemias / Q000139:chemically induced* / Q000378:metabolism; D044882:Glucose Metabolism Disorders / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007333:Insulin Resistance; D001523:Mental Disorders / Q000188:drug therapy* / Q000378:metabolism; D009765:Obesity / Q000139:chemically induced* / Q000378:metabolism; D000077152:Olanzapine; D010640:Phenothiazines / Q000009:adverse effects; D010879:Piperazines / Q000009:adverse effects; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000009:adverse effects; D018967:Risperidone / Q000009:adverse effects; D012559:Schizophrenia / Q000188:drug therapy; D013844:Thiazoles / Q000009:adverse effects
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010640:Phenothiazines; D010879:Piperazines; D015363:Quinolones; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D000068180:Aripiprazole; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine